|
|
|
28.10.26 - 11:48
|
Roche Buy (DPA-AFX)
|
|
|
FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat die Einstufung für Roche mit einem Kursziel von 500 Franken auf "Buy" belassen. Die auf dem Onkologiekongress Esmo präsentierten Studiendaten seien leicht positiv, schrieb Emmanuel Papadakis in ......
|
|
|
|
|
|
|
|
|
|
|
28.10.26 - 07:01
|
Roche strengthens cancer diagnostic portfolio with launch of test for differential diagnosis of mesothelioma (GlobeNewswire EN)
|
|
|
Basel, 28 October 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today the global launch of the VENTANA BAP1 (SP527)* test. This automated, ready-to-use immunohistochemistry (IHC) assay provides a reliable, highly specific diagnostic tool to help clinicians and pathologists accurately identify mesothelioma and distinguish it from other malignancies, including non-small cell lung cancer (NSCLC). The BAP1 assay is registered as a Class I IVD with U.S. Food and Drug Administration, has received IVDR approval as a Class C device, and is available globally....
|
|
|
|
|
|
|
26.10.26 - 17:54
|
Aktien Schweiz etwas fester - Roche-Aktie gesucht (Dow Jones)
|
|
|
DOW JONES--Etwas fester hat der schweizerische Aktienmarkt den ersten Handelstag der Woche beendet. Für Erleichterung sorgte die Bestätigung der Bonitätseinstufung Frankreichs mit "Aa3" durch die Ratingagentur Moody's - trotz des stetigen Anstiegs der ......
|
|
|
26.10.26 - 13:09
|
Roche Neutral (DPA-AFX)
|
|
|
NEW YORK (dpa-AFX Analyser) - Die US-Bank JPMorgan hat das Kursziel für Roche von 325 auf 335 Franken angehoben, aber die Einstufung auf "Neutral" belassen. Analyst Richard Vosser hob am Sonntag in seinem Resümee des Quartalsberichts seine Schätzungen ......
|
|
|
|
|
|
|
|
|
|
|
|
|
25.10.26 - 16:33
|
Roche′s divarasib demonstrated best-in-class efficacy, advancing the standard of care in previously treated KRAS G12C-mutated lung cancer (GlobeNewswire EN)
|
|
|
Basel, 25 October 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today pivotal results from the phase III Krascendo 1 study, which demonstrated the superior efficacy of investigational divarasib, a next-generation KRAS G12C inhibitor, compared with current standard of care KRAS G12C inhibitors in people with previously treated KRAS G12C-mutated non-small cell lung cancer (NSCLC).1,2 Participants treated with divarasib monotherapy lived significantly longer, lowering the risk of death by 44% compared with sotorasib or adagrasib (overall survival, OS, HR 0.56, [95% CI: 0.41-0.78], p=0.0005).1,2 Median OS for divarasib is currently approximately 18 months, compared to 12 months for the control arm (see table below).1,2 No new safety findings were observed with divarasib and the most common treatment-related adverse events (TRAEs) were mainly low grade and manageable.1,2 These data were presented as a late-breaking abstract during a Presidential Symposium at the 2026 European Society for Medical Oncology...
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
